# US 2026/0060937 A1 · Lidocaine non-aqueous patch, 1.8% for pain associated with post-herpetic neuralgia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060937 A1
- Document ID: US20260060937A1
- Status: Published application
- Kind: A1
- Application number: 19/302,413
- Filed: 2025-08-18
- Published: 2026-03-05
- Earliest claimed: 2024-08-27
- Assignees: Stira Pharmaceuticals LLC
- Applicants: Stira Pharmaceuticals LLC
- Inventors: Satyanarayana VALIVETI; Surya NALLURI; Phani Prasanth TIRUMALASETTY
- Web page: https://patentgrep.com/patent/US20260060937A1

## CPC

- A61K 9/7053: {obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 47/02: Inorganic compounds
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a lidocaine non-aqueous topical patch composition comprising approximately 1.8% w/w lidocaine incorporated into a non-aqueous adhesive matrix containing high and low molecular weight polyisobutylenes, hydrogenated polybutene, styrene-isoprene-styrene block copolymer, mineral oil, isopropyl myristate, silicon dioxide, and optionally antioxidants. The formulation provides enhanced skin permeation and sustained drug release with minimal crystallization. The patch is manufactured using a solvent-coating process with toluene, followed by drying and lamination to achieve desired coat weight and adhesive properties. The patch is effective for treating pain conditions such as post-herpetic neuralgia and offers improved stability, ease of application, and reduced risk of irritation.

## Claims

### Claim 1

A lidocaine non-aqueous patch, comprising:
about 1.8% w/w lidocaine in a non-aqueous base,
high molecular weight polyisobutylene,
low molecular weight polyisobutylene,
polybutene,
styrene/isoprene/styrene block copolymer,
mineral oil,
silicon dioxide, and
isopropyl myristate.

### Claim 2 (depends on 1)

The lidocaine non-aqueous patch of claim 1, wherein the release ratio of lidocaine from the patch is greater than 6% w/w after 12 hours of attachment to the skin.

### Claim 3 (depends on 1)

The lidocaine non-aqueous patch of claim 1, wherein the amount of lidocaine is between 0.1 mg/cm2 and 1 mg/cm2 of the patch.

### Claim 4 (depends on 1)

The lidocaine non-aqueous patch of claim 1, wherein the concentration of styrene/isoprene/styrene block copolymer is between 20% w/w and 25% w/w.

### Claim 5 (depends on 1)

The lidocaine non-aqueous patch of claim 1, wherein the concentration of isopropyl myristate is between 5% w/w and 10% w/w.

### Claim 6 (depends on 1)

The lidocaine non-aqueous patch of claim 1, wherein the concentration of mineral oil is between 5% w/w and 15% w/w.

### Claim 7 (depends on 1)

The lidocaine non-aqueous patch of claim 1, wherein the ratio of isopropyl myristate to mineral oil is between 1:2 and 1:3 by weight.

### Claim 8 (depends on 1)

The lidocaine non-aqueous patch of claim 1, further comprising zinc oxide, zinc stearate, and an antioxidant.

### Claim 9 (depends on 1)

The lidocaine non-aqueous patch of claim 1, wherein the patch is prepared using a solvent coating process comprising the steps of mixing all excipients in an organic solvent, followed by coating and drying to achieve a desired coat weight.

### Claim 10 (depends on 9)

The lidocaine non-aqueous patch of claim 9, wherein the solvent is toluene.

### Claim 11 (depends on 9)

The lidocaine non-aqueous patch of claim 9, wherein the patch is prepared by placing styrene/isoprene/styrene block copolymer, polyisobutylene, polybutene, silicon dioxide, butylated hydroxytoluene, mineral oil, isopropyl myristate, and lidocaine into toluene, and the resulting solution is coated onto a polyester film to achieve a desired coat weight.

### Claim 12 (depends on 9)

The lidocaine non-aqueous patch of claim 9, wherein the patch is prepared by dispensing toluene into a mixing vessel, adding colloidal silicon dioxide, mineral oil, isopropyl myristate, and lidocaine, and stirring until the lidocaine is dissolved and the silicon dioxide is dispersed; then adding styrene/isoprene/styrene block copolymer and stirring until solvated; followed by sequential addition of high molecular weight and low molecular weight polyisobutylene and polybutene, and mixing until a homogeneous mixture is achieved.

### Claim 13 (depends on 12)

The lidocaine non-aqueous patch of claim 12, wherein the homogeneous drug-in-adhesive mixture is coated onto a polyethylene terephthalate (PET) film and dried to achieve a target coat weight, and the dried laminate is laminated with a non-woven fabric.

### Claim 14 (depends on 13)

The lidocaine non-aqueous patch of claim 13, wherein a second layer of the drug-in-adhesive mixture is coated onto a PET liner to achieve the target coat weight, and the second layer is laminated with the previously coated non-woven fabric, sandwiching the adhesive layer between the non-woven fabric and the PET release liner.

### Claim 15 (depends on 13)

The lidocaine non-aqueous patch of claim 13, wherein the target coat weight is about 14.28 mg/cm2.

### Claim 16 (depends on 1)

The lidocaine non-aqueous patch of claim 1, wherein the formulation is free of lidocaine crystallization under storage conditions for at least four weeks.

### Claim 17 (depends on 1)

The lidocaine non-aqueous patch of claim 1, wherein the patch exhibits physical and chemical stability under at least one of the following storage conditions: refrigerated (4° C.±2° C.), controlled room temperature (25° C.±2° C., 60% RH±5% RH), or accelerated conditions (40° C.±2° C., 75% RH±5% RH) for at least four weeks without lidocaine crystallization or significant degradation of lidocaine.

### Claim 18 (depends on 1)

The lidocaine non-aqueous patch of claim 1, wherein the patch provides a lidocaine flux of between 2.5 μg/cm2/hour to 3.5 μg/cm2/hour over a 12-hour period as determined by in-vitro permeation testing using Franz diffusion cells and human cadaver skin.

### Claim 19 (depends on 1)

A method of treating pain associated with post-herpetic neuralgia, comprising applying the lidocaine non-aqueous patch of claim 1 to an affected area of skin, thereby providing pain relief without causing significant skin irritation.

### Claim 20 (depends on 1)

A packaged pharmaceutical product comprising the lidocaine non-aqueous patch of claim 1 enclosed within a moisture-impermeable pouch.
